Kenvue (NYSE:KVUE) Posts Quarterly Earnings Results, Beats Expectations By $0.05 EPS

Kenvue (NYSE:KVUE) announced its quarterly earnings results on Tuesday. The company reported $0.27 EPS for the quarter, beating the consensus estimate of $0.22 by $0.05, FiscalAI reports. The business had revenue of $3.78 billion during the quarter, compared to analysts’ expectations of $3.68 billion. Kenvue had a return on equity of 19.86% and a net margin of 9.72%.The firm’s quarterly revenue was up 3.2% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.26 EPS.

Kenvue Price Performance

NYSE KVUE opened at $18.87 on Thursday. The stock has a 50-day simple moving average of $17.48 and a 200 day simple moving average of $17.66. Kenvue has a twelve month low of $14.02 and a twelve month high of $25.17. The stock has a market capitalization of $36.15 billion, a PE ratio of 24.51 and a beta of 0.59. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.69 and a current ratio of 0.98.

Kenvue Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, February 25th. Stockholders of record on Wednesday, February 11th will be paid a $0.2075 dividend. The ex-dividend date is Wednesday, February 11th. This represents a $0.83 dividend on an annualized basis and a dividend yield of 4.4%. Kenvue’s payout ratio is presently 110.67%.

Wall Street Analysts Forecast Growth

KVUE has been the topic of a number of recent research reports. Zacks Research upgraded shares of Kenvue from a “strong sell” rating to a “hold” rating in a report on Wednesday, November 26th. Evercore set a $18.00 target price on Kenvue in a report on Tuesday, October 28th. Citigroup boosted their price target on Kenvue from $18.00 to $20.00 and gave the stock a “neutral” rating in a research report on Wednesday. Johnson Rice reissued a “neutral” rating on shares of Kenvue in a report on Tuesday, October 28th. Finally, Weiss Ratings reissued a “hold (c-)” rating on shares of Kenvue in a research note on Friday, January 9th. Four investment analysts have rated the stock with a Buy rating and twelve have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $20.08.

Insider Buying and Selling

In other Kenvue news, Director Jeffrey C. Smith purchased 3,200,000 shares of the business’s stock in a transaction dated Friday, December 12th. The stock was bought at an average cost of $17.37 per share, for a total transaction of $55,584,000.00. Following the completion of the acquisition, the director directly owned 27,307,632 shares in the company, valued at $474,333,567.84. This represents a 13.27% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 1.68% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Kenvue

Several large investors have recently added to or reduced their stakes in the company. State Street Corp grew its holdings in shares of Kenvue by 3.5% during the 4th quarter. State Street Corp now owns 118,865,134 shares of the company’s stock worth $2,050,424,000 after purchasing an additional 4,063,257 shares in the last quarter. Starboard Value LP lifted its position in Kenvue by 30.5% in the fourth quarter. Starboard Value LP now owns 27,307,632 shares of the company’s stock worth $471,057,000 after purchasing an additional 6,377,694 shares during the period. Northern Trust Corp lifted its position in Kenvue by 1.0% in the fourth quarter. Northern Trust Corp now owns 19,420,240 shares of the company’s stock worth $334,999,000 after purchasing an additional 190,760 shares during the period. Amundi boosted its stake in Kenvue by 21.6% during the third quarter. Amundi now owns 17,645,761 shares of the company’s stock worth $277,012,000 after buying an additional 3,135,871 shares in the last quarter. Finally, Cibc World Markets Corp bought a new stake in Kenvue in the 4th quarter valued at $162,193,000. Institutional investors and hedge funds own 97.64% of the company’s stock.

About Kenvue

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.